|
1) Yusuf S, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-59
|
|
|
|
2) Okaishi K, et al. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am J Hypertens. 1999; 12: 778-83
|
|
|
|
|
|
3) van de Garde EM, et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006; 27: 1217-22
|
|
|
|
|
|
4) van de Garde EM, et al. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens. 2007; 25: 235-9
|
|
|
|
|
|
5) Nakao N, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361: 117-24
|
|
|
|
|
|
6) Bakris GL, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007; 72: 879-85
|
|
|
|
|
|
7) Cohn JN, et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75
|
|
|
|
|
|
8) Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-66
|
|
|
|
|
|
9) Hu J, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001; 276: 47863-8
|
|
|
|
|
|
10) Hemming ML, et al. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005; 280: 37644-50
|
|
|
|
|
|
11) Eckman EA, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem. 2006; 281: 30471-8
|
|
|
|
|
|
12) Kehoe PG, et al. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease？ Lancet Neurol. 2007; 6: 373-8
|
|
|
|
|
|
13) Khachaturian AS, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006; 63: 686-92
|
|
|
|
|
|
14) Wang J, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007; 117: 3393-402
|
|
|
|
|
|
15) Benson SC, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43: 993-1002
|
|
|
|
|